RHYTHM PHARMACEUTICALS, INC.
Congressional Trades
No congressional trades in RYTM on record.
Whale Activity
- Increased128
- New52
- Held56
- Decreased80
- Closed26
- No prior filing18
| Filer | Shares | Value | Change |
|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 6.7M | $634.8M | held |
| BlackRock, Inc. | 6.0M | $568.9M | decreased |
| BAKER BROS. ADVISORS LP | 5.6M | $533.6M | held |
| JPMORGAN CHASE & CO | 3.6M | $340.8M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.1M | $299.8M | increased |
| PRIMECAP MANAGEMENT CO/CA/ | 3.1M | $291.8M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.0M | $286.2M | decreased |
| STATE STREET CORP | 2.6M | $251.2M | increased |
| PERCEPTIVE ADVISORS LLC | 2.5M | $241.1M | decreased |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 2.5M | $236.2M | increased |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.3M | $222.3M | decreased |
| GOLDMAN SACHS GROUP INC | 2.1M | $201.6M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Shulman JosephChief Technical Officer | Sale | −45.9K | $119.90 | $5.5M | Nov 18, 2026 | Form 4 ↗ |
| JEAN CHRISTOPHEDirector · Director | Sale | −5,000 | $106.81 | $534K | Nov 17, 2026 | Form 4 ↗ |
| JEAN CHRISTOPHEDirector · Director | Sale | −2,500 | $115.00 | $288K | Nov 17, 2026 | Form 4 ↗ |
| JEAN CHRISTOPHEDirector · Director | Sale | −2,500 | $110.00 | $275K | Nov 17, 2026 | Form 4 ↗ |
| Meeker David PPresident and CEO · Director | Sale | −2,300 | $105.19 | $242K | Sep 14, 2026 | Form 4 ↗ |
| Meeker David PPresident and CEO · Director | Sale | −1,817 | $104.55 | $190K | Sep 14, 2026 | Form 4 ↗ |
| Meeker David PPresident and CEO · Director | Sale | −8,698 | $103.43 | $900K | Sep 14, 2026 | Form 4 ↗ |
| Meeker David PPresident and CEO · Director | Sale | −30.7K | $102.35 | $3.1M | Sep 14, 2026 | Form 4 ↗ |
| Meeker David PPresident and CEO · Director | Sale | −6,439 | $101.75 | $655K | Sep 14, 2026 | Form 4 ↗ |
| Meeker David PPresident and CEO · Director | Option exercise | +50.0K | $6.05 | $303K | Sep 14, 2026 | Form 4 ↗ |
| Smith Hunter CChief Financial Officer | Sale | −28.2K | $106.20 | $3.0M | Aug 31, 2026 | Form 4 ↗ |
| Smith Hunter CChief Financial Officer | Sale | −11.5K | $105.37 | $1.2M | Aug 31, 2026 | Form 4 ↗ |
| Smith Hunter CChief Financial Officer | Sale | −23.1K | $104.59 | $2.4M | Aug 31, 2026 | Form 4 ↗ |
| Smith Hunter CChief Financial Officer | Option exercise | +57.2K | $25.79 | $1.5M | Aug 31, 2026 | Form 4 ↗ |
| Shulman JosephChief Technical Officer | Sale | −5,079 | $119.75 | $608K | Aug 13, 2026 | Form 4 ↗ |
| Shulman JosephChief Technical Officer | Option exercise | +2,024 | $6.80 | $14K | Aug 13, 2026 | Form 4 ↗ |
| Garfield AlastairChief Scientific Officer | Sale | −800 | $119.17 | $95K | Aug 13, 2026 | Form 4 ↗ |
| Garfield AlastairChief Scientific Officer | Sale | −3,400 | $118.28 | $402K | Aug 13, 2026 | Form 4 ↗ |
| Garfield AlastairChief Scientific Officer | Sale | −1,556 | $117.08 | $182K | Aug 13, 2026 | Form 4 ↗ |
| Garfield AlastairChief Scientific Officer | Sale | −2,007 | $116.11 | $233K | Aug 13, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.2M | $241.7M | 0.01% | Jun 30, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund PRIMECAP Odyssey Funds | 2.0M | $195.3M | 2.64% | Jul 31, 2026 |
| SMALLCAP World Fund Inc | 1.7M | $189.6M | 0.20% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 1.6M | $174.6M | 0.09% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 1.4M | $157.3M | 0.19% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 1.2M | $129.0M | 1.20% | Jun 30, 2026 |
| Federated Hermes Kaufmann Fund Federated Hermes Equity Funds | 1.0M | $101.9M | 2.07% | Jul 31, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 906.0K | $100.6M | 0.21% | Jun 30, 2026 |
| PRIMECAP Odyssey Growth Fund PRIMECAP Odyssey Funds | 1.0M | $100.1M | 1.65% | Jul 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 779.8K | $86.6M | 0.59% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list RYTM's shares (CUSIP 76243J105), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- JPMORGAN CHASE & CO.SCHEDULE 13G · passive (13G) · 3.6M shares5.1%
Oct 13, 2026 · ↗ - Perceptive Capital Solutions Holdings LPSCHEDULE 13G/A · passive (13G) · 729.2K shares1.1%
May 15, 2026 · ↗ - Perceptive Life Sciences Master Fund, Ltd.SCHEDULE 13G/A · passive (13G) · 2.8M shares4.1%
May 15, 2026 · ↗ - Joseph EdelmanSCHEDULE 13G/A · passive (13G) · 3.5M shares5.1%
May 15, 2026 · ↗ - Perceptive Advisors LLCSCHEDULE 13G/A · passive (13G) · 3.5M shares5.1%
May 15, 2026 · ↗ - GOLDMAN SACHS & CO. LLCSCHEDULE 13G/A · passive (13G) · 1.8M shares3.0%
Feb 10, 2025 · ↗ - THE GOLDMAN SACHS GROUP, INC.SCHEDULE 13G/A · passive (13G) · 1.8M shares3.0%
Feb 10, 2025 · ↗
Corporate Lobbying
No lobbying filings found naming RHYTHM PHARMACEUTICALS, INC. as the client.
Government Contracts
No federal contract awards found for RHYTHM PHARMACEUTICALS, INC..
U.S. Patents
No USPTO patent applications found for RHYTHM PHARMACEUTICALS, INC..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $189.8M | $130.1M | $77.4M | $23.6M | $3.2M |
| Operating income | -$192.0M | -$265.5M | -$184.4M | -$179.2M | -$170.1M |
| Net income | -$196.5M | -$260.6M | -$184.7M | -$181.1M | -$69.6M |
| Diluted EPS | -$3.11 | -$4.34 | -$3.20 | -$3.47 | -$1.40 |
| Operating cash flow | -$115.7M | -$113.9M | -$136.2M | -$173.4M | -$146.0M |
| Cash and equivalents | $54.3M | $89.1M | $60.1M | $127.7M | $59.2M |
| Total assets | $480.2M | $392.3M | $332.7M | $382.5M | $329.5M |
| Total liabilities | $210.2M | $227.7M | $163.0M | $118.2M | $45.4M |
| Shareholders' equity | $139.1M | $21.7M | $169.8M | $264.3M | $284.2M |
As RHYTHM PHARMACEUTICALS, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗
Stock Splits
No stock splits in RYTM's price history.
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 3, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 8.01, 9.01Results of operations · Reg FD disclosure · Other eventsAug 4, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 25, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsJun 15, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 5, 2026
EDGAR ↗
